LetsGetChecked Acquires Veritas Genetics and Veritas Intercontinental

LetsGetChecked Acquires BioIQ

November 16, 2021

Healthcare Services

LetsGetChecked has acquired BioIQ, an analytics-driven population health and diagnostics company, with BioIQ operating as a wholly owned subsidiary. The deal expands LetsGetChecked’s at-home diagnostics, telehealth and pharmacy capabilities and broadens its reach into health plan, employer and public-sector markets.

Veritas Genetics Acquires Curoverse

August 3, 2017

Biotechnology

Veritas Genetics has acquired Boston-based Curoverse, the creator of the Arvados open-source genomic data platform, for an undisclosed amount. The acquisition brings Curoverse’s bioinformatics, data-management and AI/ML capabilities in-house to expand Veritas’s capacity for large-scale genome interpretation and deploy machine learning across millions of genomes.

LetsGetChecked Acquires Truepill

October 1, 2024

Healthcare Services

LetsGetChecked has completed the acquisition of Truepill, a digital pharmacy platform, to integrate pharmacy technology and medication fulfillment into its at-home healthcare solutions. The deal creates a combined offering that spans testing, virtual care, and prescription delivery to support a full lifecycle of care for employers, health plans, providers, and consumer patients.

Interpace Diagnostics Acquires Cancer Genetics' Biopharma Services Business

July 15, 2019

Healthcare Services

Interpace Diagnostics Group, Inc. acquired assets and certain liabilities comprising the Biopharma Services business of Cancer Genetics, Inc. for approximately $23.5 million, with the business continuing to operate from labs in Rutherford, New Jersey and Research Triangle Park, North Carolina. In conjunction with the transaction Ampersand Capital Partners invested $27 million in Interpace via convertible preferred stock to support the acquisition and Interpace’s growth in the clinical diagnostic and biopharma services markets.

Tesis Biosciences Acquires Genome Explorations

February 16, 2022

Biotechnology

Tesis Biosciences has acquired Genome Explorations to accelerate its clinical research and product development efforts in targeted genetic sequencing and precision medicine. The acquisition brings Genome Explorations’ genomic profiling and molecular diagnostics capabilities and clinical research staff into Tesis’ integrated platform to speed development of proprietary therapeutics and diagnostic products.

Exact Sciences Acquires PreventionGenetics

January 9, 2022

Healthcare Services

Exact Sciences Corp. acquired PreventionGenetics, a CLIA- and ISO-accredited genetic testing laboratory based in Marshfield, Wisconsin, for $190 million (50% stock, 50% cash) to accelerate its entrance into hereditary cancer testing. PreventionGenetics reported preliminary 2021 revenue of about $36 million and ~100+ staff; Exact Sciences intends to leverage its commercial reach to expand hereditary cancer and genetic testing domestically and internationally.